May 1, 2018 — Cerebrovascular imaging analysis company iSchemaView received final clearance from the U.S. Food and Drug Administration (FDA) for Rapid CTA, the company’s 3-D imaging solution for computed tomography angiography. Rapid CTA is the newest addition to iSchemaView’s neuroimaging platform — including Rapid CTP and Rapid MRI — which is designed to provide physicians with fast, fully-automated and easy-to-interpret imaging that facilitates clinical decision making around cerebrovascular disease, such as stroke.
CTA provides visualization of blood vessels in the brain. Using an injectable contrast agent, high-tech X-ray imaging and sophisticated computer analysis, a CT angiogram provides physicians with detailed and accurate images of the vasculature. However, interpreting standard CTA output is a cumbersome, time-consuming process.
Rapid CTA automatically provides clear, easy to interpret CTA maps that include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple four-color-coded scale. Additionally, a 3-D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles. All of this occurs in a few minutes.
Rapid CTA is a tool for all doctors involved in neurovascular emergencies – from the emergency room (ER) doctor making decisions about patient transfer to the neurointerventionalist getting ready for an incoming thrombectomy procedure.
In an effort to save valuable diagnosis and treatment time, Rapid CTA also offers remote viewing for physicians in the hospital, at home or on the road. Image maps are immediately available to doctors for review on any desktop or mobile device.
Rapid CTA maps provide an intuitive and easy to interpret view of the brain vessels, helping physicians with:
- Clinical decision making;
- Patient triage;
- Collaboration between community hospitals and specialists; and
- Appropriate patient transfers to specialty centers.
For more information: www.irapid.com
May 02, 2025 
